Table 1.
Baseline characteristics of dogs undergoing transcatheter edge-to-edge mitral valve repair.
| n = 50 | |
|---|---|
| Age (years) | 9.9 (8.7, 11.3) |
| Female (number (percent)) | 13 (26%) |
| Body weight (kg) | 7.9 (6.1, 9.4) |
|
Breed CKCS (number (percent)) |
13 (26%) |
| Heart rate (bpm) | 118 (96, 130) |
| Systolic blood pressure (mmHg) | 132 (120, 145) |
|
Cardiac rhythm Sinus rhythm/sinus tachycardia Atrial premature complexes Ventricular premature complexes |
50 (100%) 2 (4%) 1 (2%) |
| Acquired atrial septal defect | 3 (6%) |
|
ACVIM Stage B2 C < 6 months C > 6 months D |
15 (30%) 25 (50%) 7 (14%) 3 (6%) |
|
Treatments at baseline Pimobendan ACEi Spironolactone Diuretic
|
50 (100%) 35 (70%) 28 (56%) 35 (70%) 3.7 (3.0, 5.0) 1 (2%) 1.1 |
|
Mitral valve characteristics on pre-procedural TEE A2 and P2 segment prolapse/flail A1 and/or A3 segment prolapse/flail P1 and/or P3 segment prolapse/flail Mid-systolic A-P diameter (mm) |
50 (100%) 27 (54%) 9 (18%) 19.5 (18.0, 21.0) |
Values are reported as median (25th-centile, 75th-centile) unless otherwise stated.
ACEi, angiotensin converting enzyme inhibitor; AP, anterior posterior; CKCS, Cavalier King Charles Spaniel.